Veracyte, Inc.

250 articles with Veracyte, Inc.

• Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive

  10/21/2019

  Data Being Presented at CHEST Annual Meeting 2019

• Veracyte Announces New Data Demonstrating That Envisia Genomic Classifier Improves IPF Diagnosis

  10/21/2019

  Results From Three Studies Presented at CHEST 2019 Suggest Test Increases Physicians’ Confidence in Diagnosis and Can Reduce the Need for Invasive, Risky Procedures

• Veracyte to Release Third Quarter 2019 Financial Results and Business Progress on October 22, 2019

  10/8/2019

  Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 5:00 p.m. Eastern time on the same day.

• Veracyte to Announce New Clinical Data for First Noninvasive Nasal Swab Test to Target Early Lung Cancer Detection at CHEST Annual Meeting 2019

  10/7/2019

  Veracyte, Inc. (Nasdaq: VCYT) today announced that preliminary clinical data for the company’s noninvasive nasal swab test – the first of its kind – for early detection of lung cancer will be presented at the annual meeting of the American College of Chest Physicians® (CHEST), being held October 18-23 in New Orleans.

• Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas

  9/11/2019

  RNA whole-transcriptome sequencing test informs thyroid cancer treatment decisions at time of diagnosis

• Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer

  9/3/2019

  Data support use of Afirma Xpression Atlas to inform surgery and treatment decisions at time of diagnosis

• Veracyte to Present at Upcoming Investor Conferences

  8/28/2019

  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the following upcoming investor conferences:

• Veracyte Announces Second Quarter 2019 Financial Results

  7/30/2019

  Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2019 and provided an update on recent business highlights.

• Astarte Medical Appoints Giulia Kennedy to Board of Directors

  7/16/2019

  Company expands Board with scientific expertise as it advances development of NICUtrition® platform to improve outcomes for preterm infants

• 

  BioSpace Movers and Shakers: July 3

  7/3/2019

  Biotech and pharma companies strengthen their executive leadership and board positions.

• Veracyte Names Keith Kennedy Chief Operating Officer and Chief Financial Officer

  7/1/2019

  Expanded Role Strengthens Top Tier of Company’s Executive Leadership Team

• Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019

  6/27/2019

  Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the second quarter 2019 after the close of market on Tuesday, July 30, 2019.

• Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis

  6/26/2019

  Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has begun making its next-generation Percepta® Genomic Sequencing Classifier (GSC) available to physicians, providing them with expanded lung cancer risk information that can further guide next steps for patients with suspicious lung nodules, as compared to the original Percepta test

• Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment

  6/17/2019

  Testing by Afirma GSC and Afirma XA helps reduce unnecessary surgeries and inform disease treatment

• Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

  6/10/2019

  Veracyte, Inc. (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary surgeries in thyroid cancer diagnosis, as compared to the original Afirma test

• Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis

  6/1/2019

  Veracyte, Inc. announced new data demonstrating the potential for its Afirma® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients with a rare but aggressive form of thyroid cancer concurrent with diagnosis by the company’s Afirma Genomic Sequencing Classifier (GSC).

• Veracyte Announces Participation in Two Upcoming Investor Conferences

  5/29/2019

  The William Blair 39th Annual Growth Stock Conference in Chicago on Wednesday, June 5, 2019, at 2:00 p.m. CDT.

• Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting

  5/23/2019

  American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago.

• Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis

  5/20/2019

  Researchers prospectively validated the Percepta GSC on 412 patients with lung nodules who had inconclusive results following bronchoscopy, a common nonsurgical procedure to diagnose lung cancer.

• 

  BioSpace Movers and Shakers, May 17

  5/17/2019

  Biopharma companies add new leaders to executive roles and boards of directors.